

NSW RSV (respiratory syncytial virus) Prevention Program – expansion of infant nirsevimab eligibility

Update 28 March 2025

Advice for health professionals

Please distribute to all doctors, nurses, midwives and other staff in your service

1. *Eligibility for newborn infants to receive nirsevimab has been expanded.*
2. *Infants born on or after 1 January 2025 not protected by maternal RSV vaccination or with risk conditions for severe RSV disease regardless of the mother's vaccination status are eligible to receive nirsevimab. Previously this only applied to infants born on or after 17 March 2025.*
3. *Eligible infants must be offered nirsevimab prior to hospital discharge. Eligible infants not immunised before discharge from hospital can receive nirsevimab up to 6 months of age from a GP, AMS or community health service.*

NSW RSV Prevention Program - infant nirsevimab program eligibility expanded for newborn infants

- Infants born on or after 1 January 2025 to a mother who did not receive the RSV vaccine in pregnancy or born with a risk condition that increases their risk of severe RSV disease, are now eligible to receive nirsevimab. Previously this only applied to infants born on or after 17 March 2025.
- Consider strategies to identify and recall eligible infants to administer nirsevimab.
- Refer to the resources below for eligibility information, clinical decision aids and an information sheet to ensure you are administering the right RSV vaccine or immunisation product to your patient.
- All pregnant women should be recommended to receive a single dose of Abrysvo® vaccine between 28 to 36 weeks gestation year-round, which is free under the National Immunisation Program.

Eligible neonates should be offered nirsevimab prior to hospital discharge as part of routine care

All eligible newborn infants should be offered nirsevimab prior to discharge from hospital as part of their routine newborn care. Eligible infants not immunised with nirsevimab before they are discharged from hospital can receive nirsevimab up to 6 months of age from a GP, AMS or community health service.

Ordering nirsevimab

GPs, AMSs and community health centres can order nirsevimab for eligible infants using the 'nirsevimab order form' on the NSW Vaccine Centre web portal. Complete the order form ahead of the patient's appointment. Routine delivery timeframes apply. Hospitals can order as per routine vaccine ordering procedures.

Useful Resources

- NSW RSV Prevention Program – Information for health professionals <https://www.health.nsw.gov.au/immunisation/Pages/respiratory-syncytial-virus.aspx>
- Clinical decision aid for nirsevimab (Beyfortus™) in newborn infants <https://www.health.nsw.gov.au/immunisation/pages/rsv-aid-infants.aspx>
- Clinical decision aid for nirsevimab (Beyfortus™) in infants and children up to 24 months of age who remain at risk of severe RSV disease <https://www.health.nsw.gov.au/immunisation/pages/rsv-aid-children.aspx>
- RSV vaccines and immunisation products <https://www.health.nsw.gov.au/immunisation/Documents/rsv-product-info-sheet.pdf>